JP2019532017A - がんを治療するための異なるエピトープ結合を示す複数の二重特異性結合ドメイン構築物 - Google Patents

がんを治療するための異なるエピトープ結合を示す複数の二重特異性結合ドメイン構築物 Download PDF

Info

Publication number
JP2019532017A
JP2019532017A JP2019501628A JP2019501628A JP2019532017A JP 2019532017 A JP2019532017 A JP 2019532017A JP 2019501628 A JP2019501628 A JP 2019501628A JP 2019501628 A JP2019501628 A JP 2019501628A JP 2019532017 A JP2019532017 A JP 2019532017A
Authority
JP
Japan
Prior art keywords
seq
group
bdc
epitopes
cancer antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019501628A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019532017A5 (cg-RX-API-DMAC7.html
Inventor
メーリン，クリストファー
コレンティ，コリン
オルソン，ジェイムズ
ウォルター，ローランド・ビー
バンダーラナイケ，アショク
ラースロー，ジョージ・エス
Original Assignee
フレッド ハッチンソン キャンサー リサーチ センター
フレッド ハッチンソン キャンサー リサーチ センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フレッド ハッチンソン キャンサー リサーチ センター, フレッド ハッチンソン キャンサー リサーチ センター filed Critical フレッド ハッチンソン キャンサー リサーチ センター
Publication of JP2019532017A publication Critical patent/JP2019532017A/ja
Publication of JP2019532017A5 publication Critical patent/JP2019532017A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2019501628A 2016-07-14 2017-07-14 がんを治療するための異なるエピトープ結合を示す複数の二重特異性結合ドメイン構築物 Withdrawn JP2019532017A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662362397P 2016-07-14 2016-07-14
US62/362,397 2016-07-14
US201762480230P 2017-03-31 2017-03-31
US62/480,230 2017-03-31
PCT/US2017/042264 WO2018014001A1 (en) 2016-07-14 2017-07-14 Multiple bi-specific binding domain constructs with different epitope binding to treat cancer

Publications (2)

Publication Number Publication Date
JP2019532017A true JP2019532017A (ja) 2019-11-07
JP2019532017A5 JP2019532017A5 (cg-RX-API-DMAC7.html) 2020-08-20

Family

ID=60952209

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019501628A Withdrawn JP2019532017A (ja) 2016-07-14 2017-07-14 がんを治療するための異なるエピトープ結合を示す複数の二重特異性結合ドメイン構築物

Country Status (6)

Country Link
US (1) US20190233534A1 (cg-RX-API-DMAC7.html)
EP (1) EP3484516A4 (cg-RX-API-DMAC7.html)
JP (1) JP2019532017A (cg-RX-API-DMAC7.html)
AU (1) AU2017297603A1 (cg-RX-API-DMAC7.html)
CA (1) CA3030841A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018014001A1 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023519932A (ja) * 2020-03-31 2023-05-15 フレッド ハッチンソン キャンサー センター 抗ｃｄ３３抗体及びその使用
JP2023520399A (ja) * 2020-03-31 2023-05-17 フレッド ハッチンソン キャンサー センター ヒト抗ｃｄ３３抗体及びその使用
JP2023548443A (ja) * 2020-10-30 2023-11-16 ジャナックス セラピューティクス，インク． Ｃｄ２８およびｐｄ－ｌ１を標的とする多特異性抗体ならびにその使用方法

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12116406B2 (en) 2017-05-26 2024-10-15 Fred Hutchinson Cancer Center Anti-CD33 antibodies and uses thereof
MX419677B (es) * 2018-06-21 2025-01-14 Regeneron Pharma Anticuerpos anti-psma x anti-cd28 biespecíficos y usos de estos
KR20210108981A (ko) 2018-12-21 2021-09-03 에프. 호프만-라 로슈 아게 종양-표적화된 효현성 cd28 항원 결합 분자
CN109485734B (zh) * 2018-12-30 2020-05-12 广州百暨基因科技有限公司 一种靶向bcma和cd19的双特异性嵌合抗原受体及其应用
WO2020150513A1 (en) * 2019-01-17 2020-07-23 Fred Hutchinson Cancer Research Center Methods to enhance the selectivity and effectiveness of cancer treatments
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
JP7664175B2 (ja) * 2019-04-09 2025-04-17 サノフイ 三重特異性結合性タンパク質、方法、およびその使用
JOP20210298A1 (ar) 2019-05-14 2023-01-30 Provention Bio Inc طرق وتركيبات للوقاية من مرض السكري من النوع الأول
KR102878895B1 (ko) 2019-05-21 2025-10-31 노파르티스 아게 Cd19 결합 분자 및 이의 용도
EP3990022A4 (en) * 2019-06-26 2023-06-28 Memorial Sloan Kettering Cancer Center Anti-cd33 antibodies for treating cancer
JP2022539038A (ja) * 2019-06-27 2022-09-07 ヴェルソー セラピューティクス， インコーポレイテッド 骨髄細胞炎症性表現型を調節するための抗ｌｒｒｃ２５組成物及び方法、ならびにその使用
CA3173210A1 (en) * 2020-03-31 2021-10-07 Cameron J. Turtle Chimeric antigen receptors targeting cd33
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
US11919958B2 (en) 2020-08-19 2024-03-05 Xencor, Inc. Anti-CD28 compositions
KR20230166075A (ko) * 2021-02-02 2023-12-06 누맙 세러퓨틱스 아게 Ror1 및 cd3에 대한 특이성을 가지는 다중 특이적 항체
IL314993A (en) 2022-02-23 2024-10-01 Xencor Inc Anti-cd28 x anti-psma antibodies

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
SG89295A1 (en) 1991-03-15 2002-06-18 Amgen Inc Pegylation of polypeptides
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
DE69333807T2 (de) 1992-02-06 2006-02-02 Chiron Corp., Emeryville Marker für krebs und biosynthetisches bindeprotein dafür
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
JP2002540764A (ja) 1999-02-12 2002-12-03 ジェネティックス・インスチチュート・インコーポレーテッド Ｂ７分子と反応するヒト化免疫グロブリンおよびそれを用いた治療方法
WO2001014424A2 (en) 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
JP2003520828A (ja) 2000-01-27 2003-07-08 ジェネティクス インスティテュート，エルエルシー Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
EP1354600A1 (en) 2002-04-19 2003-10-22 Affimed Therapeutics AG Antibody combination useful for tumor therapy
AU2004253770C1 (en) 2003-07-02 2010-04-15 Innate Pharma PAN-KIR2DL NK-receptor antibodies and their use in diagnostik and therapy
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
ATE475669T1 (de) 2004-06-29 2010-08-15 Immunocore Ltd Einen modifizierten t-zellen-rezeptor exprimierende zellen
CA2594356C (en) 2005-01-05 2018-07-17 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
EP1896582A4 (en) 2005-05-09 2009-04-08 Ono Pharmaceutical Co HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED CELL DEATH 1 (PD-1) AND METHOD FOR CREATING TREATMENT WITH ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS
WO2008103849A2 (en) 2007-02-21 2008-08-28 The Regents Of The University Of California Methods and compounds for lymphoma cell detection and isolation
EP1829895A1 (en) 2006-03-03 2007-09-05 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies
NZ577085A (en) 2006-11-15 2012-06-29 Medarex Inc Human monoclonal antibodies to btla and methods of use
WO2008076868A2 (en) 2006-12-18 2008-06-26 Abbott Laboratories Methods and compositions related to modulation of receptor tyrosine kinase orphan receptor-1 (ror-1)
US8163279B2 (en) 2007-04-13 2012-04-24 Stemline Therapeutics, Inc. IL3Rα antibody conjugates and uses thereof
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
EP2316491B1 (en) 2008-07-18 2016-10-12 National University Corporation Nagoya University Cell proliferation inhibitor
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
WO2010065939A1 (en) 2008-12-05 2010-06-10 Indiana University Research & Technology Corporation Combination therapy to enhace nk cell mediated cytotoxicty
TW202442680A (zh) 2008-12-09 2024-11-01 美商建南德克公司 抗pd-l1抗體及其於增進t細胞功能之用途
CN102369215B (zh) 2009-04-02 2015-01-21 罗切格利卡特公司 包含全长抗体和单链Fab片段的多特异性抗体
ES2537100T3 (es) 2009-04-07 2015-06-02 Roche Glycart Ag Anticuerpos biespecíficos trivalentes
WO2010124188A1 (en) 2009-04-23 2010-10-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human ror1 antibodies
BRPI1007602A2 (pt) 2009-05-27 2016-02-16 Hoffmann La Roche "anticorpo tri ou tetraespecífico, método para preparação de um anticorpo triespecífico ou tetraespecífico, célula hospedeira, composição, composição farmacêutica e método para o tratamento de um paciente com necessidade de terapia"
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
US20120282177A1 (en) 2009-11-02 2012-11-08 Christian Rohlff ROR1 as Therapeutic and Diagnostic Target
CN102712695B (zh) 2009-12-18 2015-01-21 堪瑟拉公司 能够诱导细胞死亡的ror1生物抑制剂
US20110165161A1 (en) * 2009-12-23 2011-07-07 Shih-Yao Lin Anti-epcam antibodies that induce apoptosis of cancer cells and methods using same
JP2013519682A (ja) 2010-02-11 2013-05-30 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗ｃｄ２００抗体を使用する治療方法
WO2011159847A2 (en) 2010-06-15 2011-12-22 The Regents Of The University Of California Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof
WO2012045085A1 (en) 2010-10-01 2012-04-05 Oxford Biotherapeutics Ltd. Anti-rori antibodies
LT3018145T (lt) * 2010-10-27 2018-05-10 Amgen Research (Munich) Gmbh Priemonės ir būdai dlbcl gydymui
EP2646469B1 (en) * 2010-12-01 2017-11-01 The United States of America, as represented by The Secretary, Department of Health and Human Services Chimeric rabbit/human ror1 antibodies
GB201020995D0 (en) 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
PT2663579T (pt) 2011-01-14 2017-07-28 Univ California Terapêutica de anticorpos contra a proteína r0r-1 e métodos para sua utilização
US20140242081A1 (en) * 2011-07-18 2014-08-28 Micromet Ag Dosing regimens for treatment of cea-expressing cancers
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
SMT202100005T1 (it) * 2012-08-20 2021-05-07 Hutchinson Fred Cancer Res Metodo e composizioni per immunoterapia cellulare
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
EP2789630A1 (en) * 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
IL301714A (en) 2013-12-24 2023-05-01 Janssen Pharmaceutica Nv Antibodies and anti-VISTA fragments
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
RU2718692C2 (ru) * 2014-05-29 2020-04-13 Мэкроудженикс, Инк. Триспецифичные связывающие молекулы, которые специфически связывают антигены множества злокачественных опухолей, и способы их применения
RS62332B1 (sr) * 2014-11-26 2021-10-29 Xencor Inc Heterodimerna antitela koja vezuju cd3 i cd20

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023519932A (ja) * 2020-03-31 2023-05-15 フレッド ハッチンソン キャンサー センター 抗ｃｄ３３抗体及びその使用
JP2023520399A (ja) * 2020-03-31 2023-05-17 フレッド ハッチンソン キャンサー センター ヒト抗ｃｄ３３抗体及びその使用
JP2023548443A (ja) * 2020-10-30 2023-11-16 ジャナックス セラピューティクス，インク． Ｃｄ２８およびｐｄ－ｌ１を標的とする多特異性抗体ならびにその使用方法

Also Published As

Publication number Publication date
EP3484516A1 (en) 2019-05-22
WO2018014001A1 (en) 2018-01-18
AU2017297603A1 (en) 2019-02-14
CA3030841A1 (en) 2018-01-18
EP3484516A4 (en) 2020-03-18
US20190233534A1 (en) 2019-08-01

Similar Documents

Publication Publication Date Title
JP2019532017A (ja) がんを治療するための異なるエピトープ結合を示す複数の二重特異性結合ドメイン構築物
JP2023518049A (ja) 新規な抗原結合ドメインおよびそれを組み込んだ合成抗原受容体
AU2019301070A1 (en) Fusion constructs and methods of using thereof
IL262321B1 (en) Compositions and methods for selective protein expression
JP2021524269A (ja) メソテリン及びｃｄ１３７結合分子
US20250064934A1 (en) Genetically engineered cells having anti-cd19 / anti-cd22 chimeric antigen receptors, and uses thereof
IL297916A (en) Compositions and methods for tcr reprogramming using cd70 specific fusion proteins
TW202504914A (zh) 嵌合抗原受體及其用途
WO2022063291A1 (en) Fibronectin extra domain b (edb) -specific car-t for cancer
WO2025106626A1 (en) Genetically engineered cells expressing c-x-c chemokine receptor type 4, and uses thereof
US20250090582A1 (en) Genetically engineered cells having anti-cd133 / anti-egfr chimeric antigen receptors, and uses thereof
CN114685659B (zh) Cd22特异性人源化抗体及利用其的嵌合抗原受体
US20230265185A1 (en) Anti-cd22 single domain antibodies and therapeutic constructs
AU2021305234A1 (en) Fusion constructs and methods of using thereof
US20230381317A1 (en) Methods for controlled activation and/or expansion of genetically engineered cells using polyethylene glycol (peg) receptors
WO2025059589A1 (en) Immune cell engaging molecules
AU2023375625A1 (en) Genetically engineered cells having anti-nectin4 chimeric antigen receptors, and uses thereof
US20230212286A1 (en) Antibodies specific for cd22 and uses thereof
WO2025207798A1 (en) Genetically engineered cells having anti-cd123 chimeric antigen receptors, and uses thereof
WO2025207795A1 (en) Genetically engineered cells having anti-cd33 / anti-cd123 chimeric antigen receptors, and uses thereof
WO2025245169A1 (en) Immunotherapy cells equipped with a collagen-targeting payload
WO2020150513A1 (en) Methods to enhance the selectivity and effectiveness of cancer treatments
HK40056378B (zh) 人源化抗claudin18.2嵌合抗原受体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200709

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200709

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20210816